Try our beta test site
11 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND proteasome inhibitor [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Condition: Lymphoma, B-Cell
Intervention: Drug: PS341 (Bortezomib)
2 Completed Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas
Conditions: Solid Tumors;   Lymphoma, Non-Hodgkin
Intervention: Drug: CEP-18770
3 Completed
Has Results
A Study of IXAZOMIB in Adult Patients With Lymphoma
Condition: Lymphoma
Intervention: Drug: IXAZOMIB
4 Completed
Has Results
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Conditions: Waldenstrom's Macroglobulinemia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone
5 Active, not recruiting Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: prednisone
6 Completed PS-341 in Treating Patients With Advanced Cancer
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: bortezomib
7 Completed NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Conditions: Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Melanoma;   Lymphoma;   Multiple Myeloma
Intervention: Drug: NPI-0052 (marizomib) + vorinostat
8 Completed Phase 1 Clinical Trial in Patients With Advanced Malignancies
Condition: Advanced Malignancies
Intervention: Drug: NPI-0052
9 Completed Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Conditions: Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Multiple Myeloma;   Stage IV Chronic Lymphocytic Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;   Drug: sorafenib tosylate
10 Recruiting Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Conditions: Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
Intervention: Drug: MLN9708
11 Completed Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib

Study has passed its completion date and status has not been verified in more than two years.